{"id":8666,"date":"2026-01-06T18:40:25","date_gmt":"2026-01-06T18:40:25","guid":{"rendered":"https:\/\/stoxpo.com\/?p=8666"},"modified":"2026-01-06T18:40:25","modified_gmt":"2026-01-06T18:40:25","slug":"alumis-breaks-out-with-promising-psoriasis-data","status":"publish","type":"post","link":"https:\/\/stoxpo.com\/index.php\/2026\/01\/06\/alumis-breaks-out-with-promising-psoriasis-data\/","title":{"rendered":"Alumis Breaks Out With Promising Psoriasis Data"},"content":{"rendered":"\n<h4 class=\"wp-block-heading\">Envudeucitinib positions the biotech for a high-stakes TYK2 showdown heading into 2026<\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">Biotech stock <strong>Alumis<\/strong> (ALMS) surged more than 110% on Tuesday after the company released strong clinical data for its plaque psoriasis drug, envudeucitinib, putting it squarely in competition with established and emerging players in the immunology space.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Envudeucitinib is an oral therapy that works by selectively blocking TYK2, a kinase that plays a key role in immune system regulation. In late-stage trials, approximately 65% of patients treated for 24 weeks achieved a 90% reduction in plaque psoriasis symptoms, while more than 40% reached complete skin clearance. These results place envudeucitinib among the most effective oral therapies reported to date in this category.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The data suggest Alumis may be able to challenge treatments from <strong>Johnson &amp; Johnson<\/strong> (JNJ) and <strong>Protagonist Therapeutics<\/strong> (PTGX), whose drug icotrokinra targets IL-23, as well as <strong>Takeda Pharmaceutical<\/strong>\u2019s (TAK) TYK2 inhibitor, zasocitinib. Leerink Partners analyst Thomas Smith said the results appear competitive with other late-stage oral psoriasis programs and could reduce risk across additional inflammatory indications where TYK2 plays a role.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Importantly, patients responded quickly. Clear separation from placebo was seen as early as week four, supporting the potential for class-leading efficacy. Alumis Chief Medical Officer Jorn Drappa described the data as demonstrating \u201cthe full promise of TYK2 inhibition.\u201d<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Safety also appeared favorable. Most side effects were mild to moderate and manageable with standard care, including headaches, colds, upper respiratory infections, and acne.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Alumis plans to submit its application to the <strong>Food and Drug Administration<\/strong> in the second half of 2026. With rivals set to present detailed data later this year, investors are now watching closely as envudeucitinib sets up what could be a defining competitive battle in psoriasis treatment.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">You might like this article:<a href=\"https:\/\/stoxpo.com\/index.php\/2026\/01\/06\/lithiums-comeback-why-albemarle-could-be-poised-for-a-strong-2026\/\"><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-vivid-cyan-blue-color\">Lithium\u2019s Comeback: Why Albemarle Could Be Poised for a Strong 2026<\/mark><\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Envudeucitinib positions the biotech for a high-stakes TYK2 showdown heading into 2026 Biotech stock Alumis (ALMS) surged more than 110% on Tuesday after the company released strong clinical data for its plaque psoriasis drug, envudeucitinib, putting it squarely in competition with established and emerging players in the immunology space. Envudeucitinib is an oral therapy that [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":5518,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"jnews-multi-image_gallery":[],"jnews_single_post":[],"jnews_primary_category":[],"jnews_social_meta":[],"jnews_override_counter":[],"jnews_post_split":[],"footnotes":""},"categories":[308,361],"tags":[884,421,831,416,418,417,885],"coauthors":[453],"class_list":["post-8666","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-biotechnology","category-large-cap","tag-alms","tag-growth","tag-jnj","tag-movers","tag-news","tag-stock-market","tag-tak"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Alumis Breaks Out With Promising Psoriasis Data - Stoxpo<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/stoxpo.com\/index.php\/2026\/01\/06\/alumis-breaks-out-with-promising-psoriasis-data\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Alumis Breaks Out With Promising Psoriasis Data - Stoxpo\" \/>\n<meta property=\"og:description\" content=\"Envudeucitinib positions the biotech for a high-stakes TYK2 showdown heading into 2026 Biotech stock Alumis (ALMS) surged more than 110% on Tuesday after the company released strong clinical data for its plaque psoriasis drug, envudeucitinib, putting it squarely in competition with established and emerging players in the immunology space. Envudeucitinib is an oral therapy that [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/stoxpo.com\/index.php\/2026\/01\/06\/alumis-breaks-out-with-promising-psoriasis-data\/\" \/>\n<meta property=\"og:site_name\" content=\"Stoxpo\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-06T18:40:25+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/stoxpo.com\/wp-content\/uploads\/2024\/10\/pexels-edward-jenner-4031323-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1707\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Liliana Vida\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Liliana Vida\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2026\\\/01\\\/06\\\/alumis-breaks-out-with-promising-psoriasis-data\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2026\\\/01\\\/06\\\/alumis-breaks-out-with-promising-psoriasis-data\\\/\"},\"author\":{\"name\":\"Liliana Vida\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#\\\/schema\\\/person\\\/db8b371dfcaa698eaedb5afa5e713fb1\"},\"headline\":\"Alumis Breaks Out With Promising Psoriasis Data\",\"datePublished\":\"2026-01-06T18:40:25+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2026\\\/01\\\/06\\\/alumis-breaks-out-with-promising-psoriasis-data\\\/\"},\"wordCount\":302,\"publisher\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2026\\\/01\\\/06\\\/alumis-breaks-out-with-promising-psoriasis-data\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/stoxpo.com\\\/wp-content\\\/uploads\\\/2024\\\/10\\\/pexels-edward-jenner-4031323-scaled.jpg\",\"keywords\":[\"ALMS\",\"Growth\",\"JNJ\",\"Movers\",\"News\",\"Stock Market\",\"TAK\"],\"articleSection\":[\"Biotechnology\",\"Large-Cap\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2026\\\/01\\\/06\\\/alumis-breaks-out-with-promising-psoriasis-data\\\/\",\"url\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2026\\\/01\\\/06\\\/alumis-breaks-out-with-promising-psoriasis-data\\\/\",\"name\":\"Alumis Breaks Out With Promising Psoriasis Data - Stoxpo\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2026\\\/01\\\/06\\\/alumis-breaks-out-with-promising-psoriasis-data\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2026\\\/01\\\/06\\\/alumis-breaks-out-with-promising-psoriasis-data\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/stoxpo.com\\\/wp-content\\\/uploads\\\/2024\\\/10\\\/pexels-edward-jenner-4031323-scaled.jpg\",\"datePublished\":\"2026-01-06T18:40:25+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2026\\\/01\\\/06\\\/alumis-breaks-out-with-promising-psoriasis-data\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2026\\\/01\\\/06\\\/alumis-breaks-out-with-promising-psoriasis-data\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2026\\\/01\\\/06\\\/alumis-breaks-out-with-promising-psoriasis-data\\\/#primaryimage\",\"url\":\"https:\\\/\\\/stoxpo.com\\\/wp-content\\\/uploads\\\/2024\\\/10\\\/pexels-edward-jenner-4031323-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/stoxpo.com\\\/wp-content\\\/uploads\\\/2024\\\/10\\\/pexels-edward-jenner-4031323-scaled.jpg\",\"width\":2560,\"height\":1707},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2026\\\/01\\\/06\\\/alumis-breaks-out-with-promising-psoriasis-data\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/stoxpo.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Alumis Breaks Out With Promising Psoriasis Data\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#website\",\"url\":\"https:\\\/\\\/stoxpo.com\\\/\",\"name\":\"Stoxpo\",\"description\":\"Stock Market &amp; Financial News\",\"publisher\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/stoxpo.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#organization\",\"name\":\"Stoxpo\",\"url\":\"https:\\\/\\\/stoxpo.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/stoxpo.com\\\/wp-content\\\/uploads\\\/2024\\\/02\\\/4q4p91-LogoMakr.png\",\"contentUrl\":\"https:\\\/\\\/stoxpo.com\\\/wp-content\\\/uploads\\\/2024\\\/02\\\/4q4p91-LogoMakr.png\",\"width\":250,\"height\":250,\"caption\":\"Stoxpo\"},\"image\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#\\\/schema\\\/person\\\/db8b371dfcaa698eaedb5afa5e713fb1\",\"name\":\"Liliana Vida\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/68bef66f029f68660c9d513c7abee60cc2c1cc99a1c80c13e95592bed4296cfd?s=96&d=mm&r=ga2a6b2037962b89d9d0225f04f06bac6\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/68bef66f029f68660c9d513c7abee60cc2c1cc99a1c80c13e95592bed4296cfd?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/68bef66f029f68660c9d513c7abee60cc2c1cc99a1c80c13e95592bed4296cfd?s=96&d=mm&r=g\",\"caption\":\"Liliana Vida\"},\"description\":\"Liliana is a seasoned financial journalist with enthusiasm for unraveling the complexities of market fluctuations and identifying paradigm-shifting trends within the stock market landscape. With years of experience in covering the stock market and publicly traded companies, Liliana has honed her skills in turning press releases into concise, informative articles. For tips and inquiries, reach out to Liliana at tips@stoxpo.com.\",\"url\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/author\\\/stoxpo-com\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Alumis Breaks Out With Promising Psoriasis Data - Stoxpo","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/stoxpo.com\/index.php\/2026\/01\/06\/alumis-breaks-out-with-promising-psoriasis-data\/","og_locale":"en_US","og_type":"article","og_title":"Alumis Breaks Out With Promising Psoriasis Data - Stoxpo","og_description":"Envudeucitinib positions the biotech for a high-stakes TYK2 showdown heading into 2026 Biotech stock Alumis (ALMS) surged more than 110% on Tuesday after the company released strong clinical data for its plaque psoriasis drug, envudeucitinib, putting it squarely in competition with established and emerging players in the immunology space. Envudeucitinib is an oral therapy that [&hellip;]","og_url":"https:\/\/stoxpo.com\/index.php\/2026\/01\/06\/alumis-breaks-out-with-promising-psoriasis-data\/","og_site_name":"Stoxpo","article_published_time":"2026-01-06T18:40:25+00:00","og_image":[{"width":2560,"height":1707,"url":"https:\/\/stoxpo.com\/wp-content\/uploads\/2024\/10\/pexels-edward-jenner-4031323-scaled.jpg","type":"image\/jpeg"}],"author":"Liliana Vida","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Liliana Vida","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/stoxpo.com\/index.php\/2026\/01\/06\/alumis-breaks-out-with-promising-psoriasis-data\/#article","isPartOf":{"@id":"https:\/\/stoxpo.com\/index.php\/2026\/01\/06\/alumis-breaks-out-with-promising-psoriasis-data\/"},"author":{"name":"Liliana Vida","@id":"https:\/\/stoxpo.com\/#\/schema\/person\/db8b371dfcaa698eaedb5afa5e713fb1"},"headline":"Alumis Breaks Out With Promising Psoriasis Data","datePublished":"2026-01-06T18:40:25+00:00","mainEntityOfPage":{"@id":"https:\/\/stoxpo.com\/index.php\/2026\/01\/06\/alumis-breaks-out-with-promising-psoriasis-data\/"},"wordCount":302,"publisher":{"@id":"https:\/\/stoxpo.com\/#organization"},"image":{"@id":"https:\/\/stoxpo.com\/index.php\/2026\/01\/06\/alumis-breaks-out-with-promising-psoriasis-data\/#primaryimage"},"thumbnailUrl":"https:\/\/stoxpo.com\/wp-content\/uploads\/2024\/10\/pexels-edward-jenner-4031323-scaled.jpg","keywords":["ALMS","Growth","JNJ","Movers","News","Stock Market","TAK"],"articleSection":["Biotechnology","Large-Cap"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/stoxpo.com\/index.php\/2026\/01\/06\/alumis-breaks-out-with-promising-psoriasis-data\/","url":"https:\/\/stoxpo.com\/index.php\/2026\/01\/06\/alumis-breaks-out-with-promising-psoriasis-data\/","name":"Alumis Breaks Out With Promising Psoriasis Data - Stoxpo","isPartOf":{"@id":"https:\/\/stoxpo.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/stoxpo.com\/index.php\/2026\/01\/06\/alumis-breaks-out-with-promising-psoriasis-data\/#primaryimage"},"image":{"@id":"https:\/\/stoxpo.com\/index.php\/2026\/01\/06\/alumis-breaks-out-with-promising-psoriasis-data\/#primaryimage"},"thumbnailUrl":"https:\/\/stoxpo.com\/wp-content\/uploads\/2024\/10\/pexels-edward-jenner-4031323-scaled.jpg","datePublished":"2026-01-06T18:40:25+00:00","breadcrumb":{"@id":"https:\/\/stoxpo.com\/index.php\/2026\/01\/06\/alumis-breaks-out-with-promising-psoriasis-data\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/stoxpo.com\/index.php\/2026\/01\/06\/alumis-breaks-out-with-promising-psoriasis-data\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/stoxpo.com\/index.php\/2026\/01\/06\/alumis-breaks-out-with-promising-psoriasis-data\/#primaryimage","url":"https:\/\/stoxpo.com\/wp-content\/uploads\/2024\/10\/pexels-edward-jenner-4031323-scaled.jpg","contentUrl":"https:\/\/stoxpo.com\/wp-content\/uploads\/2024\/10\/pexels-edward-jenner-4031323-scaled.jpg","width":2560,"height":1707},{"@type":"BreadcrumbList","@id":"https:\/\/stoxpo.com\/index.php\/2026\/01\/06\/alumis-breaks-out-with-promising-psoriasis-data\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/stoxpo.com\/"},{"@type":"ListItem","position":2,"name":"Alumis Breaks Out With Promising Psoriasis Data"}]},{"@type":"WebSite","@id":"https:\/\/stoxpo.com\/#website","url":"https:\/\/stoxpo.com\/","name":"Stoxpo","description":"Stock Market &amp; Financial News","publisher":{"@id":"https:\/\/stoxpo.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/stoxpo.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/stoxpo.com\/#organization","name":"Stoxpo","url":"https:\/\/stoxpo.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/stoxpo.com\/#\/schema\/logo\/image\/","url":"https:\/\/stoxpo.com\/wp-content\/uploads\/2024\/02\/4q4p91-LogoMakr.png","contentUrl":"https:\/\/stoxpo.com\/wp-content\/uploads\/2024\/02\/4q4p91-LogoMakr.png","width":250,"height":250,"caption":"Stoxpo"},"image":{"@id":"https:\/\/stoxpo.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/stoxpo.com\/#\/schema\/person\/db8b371dfcaa698eaedb5afa5e713fb1","name":"Liliana Vida","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/68bef66f029f68660c9d513c7abee60cc2c1cc99a1c80c13e95592bed4296cfd?s=96&d=mm&r=ga2a6b2037962b89d9d0225f04f06bac6","url":"https:\/\/secure.gravatar.com\/avatar\/68bef66f029f68660c9d513c7abee60cc2c1cc99a1c80c13e95592bed4296cfd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/68bef66f029f68660c9d513c7abee60cc2c1cc99a1c80c13e95592bed4296cfd?s=96&d=mm&r=g","caption":"Liliana Vida"},"description":"Liliana is a seasoned financial journalist with enthusiasm for unraveling the complexities of market fluctuations and identifying paradigm-shifting trends within the stock market landscape. With years of experience in covering the stock market and publicly traded companies, Liliana has honed her skills in turning press releases into concise, informative articles. For tips and inquiries, reach out to Liliana at tips@stoxpo.com.","url":"https:\/\/stoxpo.com\/index.php\/author\/stoxpo-com\/"}]}},"_links":{"self":[{"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/posts\/8666","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/comments?post=8666"}],"version-history":[{"count":1,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/posts\/8666\/revisions"}],"predecessor-version":[{"id":8667,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/posts\/8666\/revisions\/8667"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/media\/5518"}],"wp:attachment":[{"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/media?parent=8666"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/categories?post=8666"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/tags?post=8666"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/coauthors?post=8666"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}